This systematic review and meta-analysis combined data from randomized controlled trials involving 3,483 patients with advanced prostate cancer. The group included those with non-metastatic castration-resistant prostate cancer and metastatic hormone-sensitive prostate cancer. Participants received either darolutamide combined with androgen deprivation therapy or placebo plus androgen deprivation therapy.
The analysis found that the combination therapy significantly prolonged overall survival and metastasis-free survival for patients with non-metastatic castration-resistant prostate cancer. Results were also favorable for overall survival in patients with metastatic hormone-sensitive prostate cancer. These findings suggest a beneficial effect for these specific patient groups.
Safety data indicated a favorable safety profile. The study reported that the treatment did not lead to serious adverse events such as heart failure, bone fracture, or hypertension. No specific discontinuations were reported. Readers should note that this is a meta-analysis of existing trials rather than a single new experiment. The results support the use of this combination therapy but do not replace individual medical advice.